Cargando…

The heterogeneity of Parkinson’s disease

The heterogeneity of Parkinson’s disease (PD), i.e. the various clinical phenotypes, pathological findings, genetic predispositions and probably also the various implicated pathophysiological pathways pose a major challenge for future research projects and therapeutic trail design. We outline severa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wüllner, Ullrich, Borghammer, Per, Choe, Chi-un, Csoti, Ilona, Falkenburger, Björn, Gasser, Thomas, Lingor, Paul, Riederer, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Vienna 2023
Materias:	Neurology and Preclinical Neurological Studies - Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10174621/ https://www.ncbi.nlm.nih.gov/pubmed/37169935 http://dx.doi.org/10.1007/s00702-023-02635-4

Ejemplares similares

Life style and Parkinson’s disease
por: Reichmann, Heinz, et al.
Publicado: (2022)

Parkinson’s disease between internal medicine and neurology
por: Csoti, Ilona, et al.
Publicado: (2015)

Blood-based biomarker in Parkinson’s disease: potential for future applications in clinical research and practice
por: Tönges, Lars, et al.
Publicado: (2022)

Adaptive changes in striatal projection neurons explain the long duration response and the emergence of dyskinesias in patients with Parkinson’s disease
por: Falkenburger, Björn, et al.
Publicado: (2022)

Blood neurofilament light chain in Parkinson’s disease
por: Buhmann, Carsten, et al.
Publicado: (2023)

Genetic testing for Parkinson’s disease in clinical practice
por: Gasser, Thomas
Publicado: (2023)

L-DOPA-therapy in Parkinson’s disease: some personal reflections on L-DOPA therapy from Vienna and Berlin
por: Riederer, Peter, et al.
Publicado: (2023)

Parkinson’s disease therapy: what lies ahead?
por: Wolff, Andreas, et al.
Publicado: (2023)

Classification of advanced stages of Parkinson’s disease: translation into stratified treatments
por: Krüger, Rejko, et al.
Publicado: (2017)

Iron as the concert master in the pathogenic orchestra playing in sporadic Parkinson’s disease
por: Riederer, P., et al.
Publicado: (2021)

Serum neurofilament light chain and postural instability/gait difficulty (PIGD) subtypes of Parkinson’s disease in the MARK-PD study
por: Pötter-Nerger, Monika, et al.
Publicado: (2022)

Lewy bodies, iron, inflammation and neuromelanin: pathological aspects underlying Parkinson’s disease
por: Riederer, Peter, et al.
Publicado: (2023)

Shared cerebral metabolic pathology in non-transgenic animal models of Alzheimer's and Parkinson's disease
por: Barilar, Jelena Osmanovic, et al.
Publicado: (2020)

Best practice approaches to outpatient management of people living with Parkinson’s disease during the COVID-19 pandemic
por: Demleitner, Antonia F., et al.
Publicado: (2022)

The role of tyrosine hydroxylase as a key player in neuromelanin synthesis and the association of neuromelanin with Parkinson’s disease
por: Nagatsu, Toshiharu, et al.
Publicado: (2023)

SARS-CoV-2 and neurodegenerative diseases: what we know and what we don’t
por: Lingor, Paul, et al.
Publicado: (2022)

Plasma autoantibodies to glial fibrillary acidic protein (GFAP) react with brain areas according to Braak staging of Parkinson’s disease
por: Gschmack, Eva, et al.
Publicado: (2022)

GBA-associated PD: chances and obstacles for targeted treatment strategies
por: Höglinger, Günter, et al.
Publicado: (2022)

Coronaviruses: a challenge of today and a call for extended human postmortem brain analyses
por: Riederer, Peter, et al.
Publicado: (2020)

Vagus Nerve Cross-Sectional Area in Patients With Parkinson's Disease—An Ultrasound Case-Control Study
por: Horsager, Jacob, et al.
Publicado: (2021)

Emotional well-being and pain could be a greater determinant of quality of life compared to motor severity in cervical dystonia
por: Klingelhoefer, Lisa, et al.
Publicado: (2020)

Amantadine: reappraisal of the timeless diamond—target updates and novel therapeutic potentials
por: Danysz, Wojciech, et al.
Publicado: (2021)

Clinical benefit of MAO-B and COMT inhibition in Parkinson’s disease: practical considerations
por: Regensburger, Martin, et al.
Publicado: (2023)

Neuroprotection in Parkinson’s disease: facts and hopes
por: Salamon, András, et al.
Publicado: (2019)

Viruses, parkinsonism and Parkinson’s disease: the past, present and future
por: Leta, Valentina, et al.
Publicado: (2022)

The Gut Dysmotility Questionnaire for Parkinson's disease: Insights into development and pretest studies
por: Raeder, Vanessa, et al.
Publicado: (2023)

Selegiline: a molecule with innovative potential
por: Tábi, Tamás, et al.
Publicado: (2019)

Glucocerebrosidase mutations and Parkinson disease
por: Vieira, Sophia R. L., et al.
Publicado: (2022)

Treatment of Parkinson’s disease in the advanced stage
por: Ossig, C., et al.
Publicado: (2013)

Small intestine dysfunction in Parkinson’s disease
por: Dutkiewicz, Justyna, et al.
Publicado: (2015)

Levodopa improves handwriting and instrumental tasks in previously treated patients with Parkinson’s disease
por: Müller, Thomas, et al.
Publicado: (2020)

A brief history of brain iron accumulation in Parkinson disease and related disorders
por: Foley, Paul B., et al.
Publicado: (2022)

Sleep and non-motor symptoms in Parkinson’s disease
por: Maass, Antonia, et al.
Publicado: (2013)

Magnetic resonance imaging for the diagnosis of Parkinson’s disease
por: Heim, Beatrice, et al.
Publicado: (2017)

Implications of dopaminergic medication withdrawal in Parkinson’s disease
por: Koschel, J., et al.
Publicado: (2021)

Disease modification in Parkinsonism: obstacles and ways forward
por: Höllerhage, M., et al.
Publicado: (2022)

The use of wearables for the diagnosis and treatment of Parkinson’s disease
por: Reichmann, Heinz, et al.
Publicado: (2023)

Neuromelanin granules of the substantia nigra: proteomic profile provides links to tyrosine hydroxylase, stress granules and lysosomes
por: Wulf, Maximilian, et al.
Publicado: (2022)

Non-motor symptoms of Parkinson’s disease: the patient’s perspective
por: Breen, Kieran C., et al.
Publicado: (2012)

Flavor perception and the risk of malnutrition in patients with Parkinson’s disease
por: Roos, Dareia S., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_vsimlrc0dqbqus46sajar6oof4